Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097). (Q34026037)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097). |
scientific article |
Statements
1 reference
Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097). (English)
1 reference
1 reference
David R Gandara
1 reference
Everett E Vokes
1 reference
Suresh S Ramalingam
1 reference
Chandra P Belani
1 reference
Philip C Mack
1 reference
Ramaswamy Govindan
1 reference
Marianna Koczywas
1 reference
S Percy Ivy
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference